FDA Orders Diasensor 1000 from Biocontrol Technology Inc.

PITTSBURGH (Feb. 9) BUSINESS WIRE- Feb. 9, 1999--Biocontrol Technology Inc. (OTC BB: BICO) announced today that it has received a purchase order from the US Food and Drug Administration (FDA) to purchase a Diasensor(R) 1000 Noninvasive Blood Glucose Monitor. The FDA's intent is not to use the Diasensor 1000 in the type of clinical investigation to support market authorization but to gain knowledge of the performance of such devices over their full range of performance.

Biocontrol Technology scientific and engineering personnel will conduct a seminar to educate the FDA staff on the use and maintenance of this particular instrument so they can evaluate its performance characteristics and conduct laboratory research on noninvasive monitoring.

The Diasensor 1000 is a home-use instrument used by patients with diabetes to measure their blood glucose without the need to prick the finger to obtain a drop of blood. Patients using currently marketed invasive devices require that patients prick their fingers to obtain a sample of blood to test their glucose. The Diasensor 1000 illuminates a small area on the patient's arm with infrared light, which is then scattered back out through the skin and collected by the instrument. This information is interpreted by software in the instrument as a blood glucose concentration.

Although not approved for sale in the US, the Diasensor 1000 is currently being marketed in the 15-nation European Union where it has been approved.

Biocontrol Technology has its corporate offices in Pittsburgh and is involved in the development and manufacture of biomedical devices and environmental products. Subsidiary Diasensor.com Inc., also located in Pittsburgh, markets the Diasensor. Diasensor.com owns the patent, marketing and distribution rights to the sensor while Biocontrol has the exclusive rights to the research and development and manufacturing of the sensor. More information is available at the Biocontrol website: www.bico.com, or by calling the investor relations newsline number at 800/357-6204.

This press release contains forward looking statements and shareholders and potential investors are cautioned that such statements are predictions and actual events or results may vary significantly.

---

LS/na*

CONTACT: Martin E. Janis & Company Inc.
Bev Jedynak, 312/943-1100

or
Biocontrol Technology Inc.

Investors: Diane McQuaide, 412/429-0673
or

Media: Susan Taylor, 412/429-0673

KEYWORD: PENNSYLVANIA
INDUSTRY KEYWORD: MEDICINE BIOTECHNOLOGY ENVIRONMENT ENMED PRODUCT
Today's News On The Net- Business Wire's full file on the Internet

with Hyperlinks to your home page.
URL: http://www.businesswire.com

n